GLO1 and HIV-1 infection: Administration of AAV2/-Endo-Glo1 five weeks post-HIV-1 infection blunted the upregulation of MG-H1, VAP-1 and the loss of Glo1 seen in hearts of Hu-mice, seventeen weeks post-HIV-1 infection (Figure 7, right panels).